Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
Globe Newswire•07/10/2026•07:05 ET
0
Key Highlights
- ➤Zenas will present seven MS posters at MSToronto2026, October 21-23, 2026
- ➤Orelabrutinib Phase 3 trial designs target non-active SPMS and primary progressive MS
- ➤Orelabrutinib 80 mg Phase 2 relapsing-remitting MS results will be presented
- ➤Obexelimab MoonStone Phase 2 results cover disease activity, biomarkers, pharmacokinetics and pharmacodynamics
- ➤SunStone Phase 2 SLE topline results expected in 4Q 2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that it will present seven posters at the 10(th) Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) taking place October 21-23, 2026, in Toronto, Canada.
The Company will also host a Symposium featuring a panel of Multiple Sclerosis (MS) experts discussing the evolving science and clinical potential of BTK inhibition in progressive MS.
Get started
Create a free account to read the full story.